CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 23 enrolled
Drug / intervention
Breast Cancer Locator (BCL)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02550210
NCT02550210N/ACompleted
CompareCT.gov

A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers

Dartmouth-Hitchcock Medical Center·interventional·Posted Sep 15, 2015·Updated Apr 30, 2019

In Brief

A clinical study evaluating Breast Cancer Locator (BCL) for Breast Cancer. Completed, enrolled 23 participants across 1 site.

Detailed Summary

In this study, the investigators will enroll women with palpable cancers to assess the accuracy of the Breast Cancer Locator (BCL) and the concomitant procedure as a vehicle to optimize and validate the approach in such surgical cases. This approach of adopting palpable cancer patients before initiating an evaluative trial of the BCL in non-palpable breast cancer cases ensures that the BCL does not substantially alter or modify the standard-of-care procedure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 15, 2015
Enrollment StartAug 1, 2015
Primary CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.8 years ago

Interventions

Breast Cancer Locator (BCL)device

This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.